D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 78 Citations 22,834 294 World Ranking 10651 National Ranking 342

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Gene
  • Cancer

His main research concerns Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Primary biliary cirrhosis and Cholestasis. His studies in Internal medicine integrate themes in fields like Endocrinology and Immunology. His work carried out in the field of Gastroenterology brings together such families of science as Liver transplantation, Incidence, Randomized controlled trial, Placebo and Cohort.

His Primary sclerosing cholangitis research incorporates themes from Genome-wide association study, Prevalence, Epidemiology, Inflammatory bowel disease and Ulcerative colitis. His Primary biliary cirrhosis study combines topics in areas such as Cirrhosis and Confidence interval. He interconnects Cholestasis of pregnancy, Lysophosphatidic acid, Autotaxin, Liver disease and Pharmacology in the investigation of issues within Cholestasis.

His most cited work include:

  • EASL Clinical Practice Guidelines: management of cholestatic liver diseases (1033 citations)
  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (534 citations)
  • Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited (513 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Cholestasis and Endocrinology. His Primary biliary cirrhosis, Ursodeoxycholic acid, Bile acid, Cirrhosis and Liver transplantation investigations are all subjects of Internal medicine research. In general Bile acid, his work in Chenodeoxycholic acid is often linked to Tauroursodeoxycholic acid linking many areas of study.

In the subject of general Gastroenterology, his work in Liver disease, Hepatology and Cholestatic pruritus is often linked to In patient, thereby combining diverse domains of study. His Primary sclerosing cholangitis research includes themes of Genome-wide association study, Liver biopsy, Inflammatory bowel disease, Immunology and Ulcerative colitis. His research in Cholestasis intersects with topics in Taurolithocholic acid, Cholestasis of pregnancy, Obeticholic acid and Autotaxin.

He most often published in these fields:

  • Internal medicine (54.15%)
  • Gastroenterology (36.59%)
  • Primary sclerosing cholangitis (23.90%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (54.15%)
  • Gastroenterology (36.59%)
  • Primary sclerosing cholangitis (23.90%)

In recent papers he was focusing on the following fields of study:

Ulrich Beuers focuses on Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Cholestasis and Endocrinology. His research on Internal medicine frequently links to adjacent areas such as Placebo. His Primary biliary cirrhosis and Hepatology study, which is part of a larger body of work in Gastroenterology, is frequently linked to In patient, bridging the gap between disciplines.

His biological study spans a wide range of topics, including Inflammatory bowel disease, Autoimmune pancreatitis, Liver disease, Proportional hazards model and Hazard ratio. His Cholestasis study incorporates themes from Cholestasis of pregnancy, Progressive familial intrahepatic cholestasis, Biliary cirrhosis, Obeticholic acid and Disease. The concepts of his Endocrinology study are interwoven with issues in Messenger RNA and Hepatocyte.

Between 2015 and 2021, his most popular works were:

  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (534 citations)
  • A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis (461 citations)
  • EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis (370 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Gene
  • Cancer

His primary areas of investigation include Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Liver transplantation and Cholestasis. His Endocrinology research extends to the thematically linked field of Internal medicine. His Gastroenterology research is multidisciplinary, relying on both Biomarker, Placebo and Surgery.

His Primary sclerosing cholangitis research incorporates elements of Inflammatory bowel disease, Autoimmune pancreatitis, Proportional hazards model, Hazard ratio and Bile duct. His research integrates issues of Autoimmune hepatitis and Primary biliary cirrhosis in his study of Liver transplantation. His work deals with themes such as Cirrhosis and Obeticholic acid, which intersect with Ursodeoxycholic acid.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

EASL Clinical Practice Guidelines: management of cholestatic liver diseases

Ulrich Beuers;Kirsten M. Boberg;Roger W. Chapman;Olivier Chazouillères.
Journal of Hepatology (2009)

1628 Citations

Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited

Gustav Paumgartner;Ulrich Beuers.
Hepatology (2002)

778 Citations

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa.
Gastroenterology (2016)

702 Citations

A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis

F. Nevens;P. Andreone;G. Mazzella;S. I. Strasser.
The New England Journal of Medicine (2016)

645 Citations

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Gideon M. Hirschfield;Ulrich Beuers;Christophe Corpechot;Pietro Invernizzi.
Journal of Hepatology (2017)

561 Citations

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review

Kirsten Boonstra;Ulrich Beuers;Cyriel Y. Ponsioen.
Journal of Hepatology (2012)

547 Citations

Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.

Ulrich Beuers.
Nature Clinical Practice Gastroenterology & Hepatology (2006)

471 Citations

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

Kirsten Boonstra;Rinse K. Weersma;Karel J. van Erpecum;Erik A. Rauws.
Hepatology (2013)

420 Citations

Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus

Andreas E. Kremer;Job J.W.W. Martens;Wim Kulik;Franziska Ruëff.
Gastroenterology (2010)

364 Citations

New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond

Ulrich Beuers;Michael Trauner;Peter Jansen;Raoul Poupon.
Journal of Hepatology (2015)

355 Citations

Editorial Boards

Journal of Hepatology
(Impact Factor: 30.083)

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ulrich Beuers

Gideon M. Hirschfield

Gideon M. Hirschfield

University Health Network

Publications: 159

Michael Trauner

Michael Trauner

Medical University of Vienna

Publications: 128

Keith D. Lindor

Keith D. Lindor

Arizona State University

Publications: 127

M. Eric Gershwin

M. Eric Gershwin

University of California, Davis

Publications: 99

Tom H. Karlsen

Tom H. Karlsen

Oslo University Hospital

Publications: 97

Pietro Invernizzi

Pietro Invernizzi

University of Milano-Bicocca

Publications: 87

David Jones

David Jones

Newcastle University

Publications: 72

Bruno Stieger

Bruno Stieger

University of Zurich

Publications: 63

Gianfranco Alpini

Gianfranco Alpini

Veterans Health Administration

Publications: 61

Ansgar W. Lohse

Ansgar W. Lohse

Universität Hamburg

Publications: 59

Dimitrios P. Bogdanos

Dimitrios P. Bogdanos

RMIT University

Publications: 55

Albert Parés

Albert Parés

University of Barcelona

Publications: 54

Michael P. Manns

Michael P. Manns

Hannover Medical School

Publications: 53

Albert J. Czaja

Albert J. Czaja

Mayo Clinic

Publications: 51

Roger W. Chapman

Roger W. Chapman

John Radcliffe Hospital

Publications: 49

Bettina E. Hansen

Bettina E. Hansen

University Health Network

Publications: 49

Trending Scientists

Mohammad Pourmahmood Aghababa

Mohammad Pourmahmood Aghababa

Urmia University of Technology

Harold F. Deutsch

Harold F. Deutsch

University of Wisconsin–Madison

Robert R. Squires

Robert R. Squires

Purdue University West Lafayette

Peter J. Roach

Peter J. Roach

Indiana University

Hisashi Arase

Hisashi Arase

Osaka University

Mark Toleman

Mark Toleman

Cardiff University

David A. Yuen

David A. Yuen

University of Minnesota

Jens Oberheide

Jens Oberheide

Clemson University

Ivan J. Fernandez

Ivan J. Fernandez

University of Maine

David J. Perkel

David J. Perkel

University of Washington

Evelyn A. Kurt-Jones

Evelyn A. Kurt-Jones

University of Massachusetts Medical School

Narcís Cardoner

Narcís Cardoner

Autonomous University of Barcelona

Namkee G. Choi

Namkee G. Choi

The University of Texas at Austin

Paul J. Kurtin

Paul J. Kurtin

Mayo Clinic

Michele C. Walsh

Michele C. Walsh

Case Western Reserve University

Donald L. Morton

Donald L. Morton

Saint John's Health Center

Something went wrong. Please try again later.